GLP-1R激动剂和心力衰竭:由孟德尔随机化推的新型有益效应
Yiqing Hu1,2,3, Yongchao Zhao4, Neng Dai1,2,3
1Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, #1609 Xietu Road, Xuhui District, Shanghai 200032, China.
European heart journal
|January 29, 2026
概括
类似葡萄糖类-1受体激动剂可降低心力衰竭风险,主要是通过降低体重指数. 其余效应表明直接的心脏保护,保证在非糖尿病,非肥胖患者的试验.
科学领域:
- 心血管研究研究心血管研究
- 内分泌学 在内分泌学.
- 遗传流行病学遗传流行病学
背景情况:
- 已知类似葡萄糖-1受体 (GLP-1R) 激动剂可降低糖尿病或肥胖患者心力衰竭 (HF) 风险.
- 这种心脏保护作用背后的精确机制,独立于血糖控制和体重减轻,需要进一步阐明.
研究的目的:
- 研究GLP-1R激活与心力衰竭风险之间的因果关系.
- 要确定血糖控制 (HbA1c) 和体重指数 (BMI) 在多大程度上调解这种效应.
主要方法:
- 两个样本的门德尔随机化 (MR) 分析利用了来自160多万参与者的全基因组关联研究数据.
- 主要分析采用了反向方差加权 (IVW) 和MR-强度调整的配置分数 (MR-RAPS) 方法.
- 先进的MR技术,包括贝叶斯模型平均和多变量MR,用于识别介质并调整混因素.
主要成果:
- 基因预测GLP-1R激活与心力衰竭风险降低显著相关 (OR:0.492-0.502).
- 身体质量指数 (BMI) 和2型糖尿病 (T2D) 被确定为关键调解因素,解释了这一效应的很大一部分.
- 即使对BMI和T2D进行调整后,HF风险的显著降低仍然存在,这表明独立的心脏保护作用.
结论:
- 通过GLP-1R激动剂调节的心力衰竭风险的降低主要是由BMI的降低驱动的,葡萄糖控制的贡献较小.
- 证据表明GLP-1R激活的直接心脏保护作用超出了代谢改善.
- 这些发现支持在更广泛的人群中,包括那些没有肥胖或糖尿病的人群中,探索GLP-1R激动剂用于HF预防.
相关概念视频
01:29Heart Failure II: Pathophysiology
907
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
907
01:17Pathophysiology of Heart Failure
3.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.6K
01:27Heart Failure I: Introduction
877
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
877
01:22Heart Failure VI: Adjunct Therapies
332
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
332
01:22Heart Failure Drugs: Diuretics
963
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
963
01:30Heart Failure V: Medical Management
308
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
308